FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera (Reuters) - British drugmaker ...

LONDON and SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory ...

On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...

GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO ® ELLIPTA ® (fluticasone furoate/vilanterol [FF/VI]) ...

(AP) A panel of respiratory experts has voted in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravence for treating chronic lung disease. A majority of Food and Drug ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and value of GSK Plc's (NYSE:GSK) chronic obstructive pulmonary disease (COPD) ...

Trelegy Ellipta is a combination of three molecules in a single inhaler. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, ...

WASHINGTON (AP) — The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease. The agency cleared the Breo Ellipta ...

Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients ...

Results from a phase 3 trial evaluating Trelegy Ellipta in patients with uncontrolled asthma showed that the single inhaler triple therapy provided a significant improvement in lung function when ...